{"organizations": [], "uuid": "373bd5af053ff7a52121569583fa61dba9f1d2e8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-progenics-pharmaceuticals-complete/brief-progenics-pharmaceuticals-completes-enrollment-in-phase-3-study-of-psma-targeted-imaging-agent-1404-idUSFWN1OX081", "country": "US", "domain_rank": 408, "title": "BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T15:46:00.000+02:00", "replies_count": 0, "uuid": "373bd5af053ff7a52121569583fa61dba9f1d2e8"}, "author": "", "url": "https://www.reuters.com/article/brief-progenics-pharmaceuticals-complete/brief-progenics-pharmaceuticals-completes-enrollment-in-phase-3-study-of-psma-targeted-imaging-agent-1404-idUSFWN1OX081", "ord_in_thread": 0, "title": "BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-progenics pharmaceuticals", "sentiment": "negative"}, {"name": "progenics pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 2, 2018 / 1:46 PM / in 13 minutes BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404 Reuters Staff \nJan 2 (Reuters) - Progenics Pharmaceuticals Inc: * PROGENICS PHARMACEUTICALS INC - \n* PROGENICS PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PSMA-TARGETED IMAGING AGENT 1404 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T15:46:00.000+02:00", "crawled": "2018-01-02T16:12:06.026+02:00", "highlightTitle": ""}